Fortress Biotech Inc

NASDAQ:FBIO   11:05:15 AM EDT
0.83
-0.05 (-5.82%)
Regulatory, Earnings Announcements

Checkpoint Therapeutics Announces Positive Interim Results From Registration-Enabling Trial Of Cosibelimab In Locally Advanced Cutaneous Squamous Cell Carcinoma

Published: 06/16/2022 11:41 GMT
Fortress Biotech Inc (FBIO) - Checkpoint Therapeutics Announces Positive Interim Results From Registration-enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma.
Checkpoint Therapeutics Inc - Objective Response Rate of 54.8% in Patients With Locally Advanced Cscc, a Potential 2(nd) Indication for Cosibelimab.
Checkpoint Therapeutics Inc - Previously Met Primary Endpoint in Patients With Metastatic Cscc; Bla Submission on Track for Later This Year.
Checkpoint Therapeutics Inc - to Continue Discussions With FDA on Potential Addition of Locally Advanced Indication to Its Planned Bla Submission.
Revenue is expected to be $23.24 Million
Adjusted EPS is expected to be -$0.16

Next Quarter Revenue Guidance is expected to be $24.13 Million
Next Quarter EPS Guidance is expected to be -$0.17

More details on our Analysts Page.